Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Gina Ma, Yi Wang, Tahmeena Ahmed, Ann Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda Shafic Salman

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

Original languageEnglish (US)
Pages (from-to)42-44
Number of pages3
JournalLeukemia Research Reports
StatePublished - 2018


  • Acute myeloid leukemia
  • Chimeric antigen receptors
  • Immunotherapy
  • Mixed phenotype acute leukemia
  • T cells

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this